Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2013


#172090

52pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Squamous Non-Small Cell Lung Cancer Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer. Squamous Non-Small Cell Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Squamous Non-Small Cell Lung Cancer.
  • A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Squamous Non-Small Cell Lung Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Squamous Non-Small Cell Lung Cancer 7
Squamous Non-Small Cell Lung Cancer Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Squamous Non-Small Cell Lung Cancer Therapeutics Products under Development by Companies 13
Companies Involved in Squamous Non-Small Cell Lung Cancer Therapeutics Development 14
Bristol-Myers Squibb Company 14
Boehringer Ingelheim GmbH 15
F. Hoffmann-La Roche Ltd. 16
Eli Lilly and Company 17
Novartis AG 18
Eisai Co., Ltd. 19
Ascenta Therapeutics, Inc. 20
Squamous Non-Small Cell Lung Cancer Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
lenvatinib - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ipilimumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
necitumumab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
onartuzumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AT-406 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Squamous Non-Small Cell Lung Cancer Therapeutics Drug Profile Updates 39
Squamous Non-Small Cell Lung Cancer Therapeutics Discontinued Products 45
Squamous Non-Small Cell Lung Cancer Product Development Milestones 46
Featured News & Press Releases 46
Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 46
May 23, 2013: OncoGenex Pharma Announces Plans For Initiation Of Cedar Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer 46
May 15, 2013: Boehringer Ingelheim To Present Six Abstracts For Nintedanib At ASCO 2013 47
Apr 08, 2013: Ariad Pharma Presents New Preclinical Data On Ponatinib At AACR Annual Meeting 2013 48
Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer 49
Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung 49
Sep 13, 2012: Oncolytics Biotech Meets Primary Endpoint For First Stage Of US Phase II Squamous Cell Lung Cancer Clinical Trial 50
Oct 29, 2010: Novotech Initiates Three Phase Ib Cancer Trials With Oncomed Pharmas Humanized Monoclonal Antibody Product In Australia And New Zealand 50

Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

Number of Products Under Development for Squamous Non-Small Cell Lung Cancer, H2 2013 7
Products under Development for Squamous Non-Small Cell Lung Cancer Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Bristol-Myers Squibb Company, H2 2013 14
F. Hoffmann-La Roche Ltd., H2 2013 16
Eli Lilly and Company, H2 2013 17
Eisai Co., Ltd., H2 2013 19
Ascenta Therapeutics, Inc., H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Squamous Non-Small Cell Lung Cancer Therapeutics Drug Profile Updates 39
Squamous Non-Small Cell Lung Cancer Therapeutics Discontinued Products 45

Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2013 7
Products under Development for Squamous Non-Small Cell Lung Cancer – Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Late Stage Products, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Early Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25